Most people know vitamin B12 deficiency from its classic blood tests — low serum B12, megaloblastic anemia. But the real question for cellular function is not how much B12 circulates in total, but how much reaches your cells. That depends almost entirely on one transport protein: transcobalamin II¹¹ transcobalamin II
The only B12-binding protein able to deliver cobalamin into cells via the CD320 receptor on cell surfaces; about 20–25% of circulating B12 is bound to this protein, forming "holotranscobalamin" (holoTC), the active fraction (TCN2). The rs5753231 variant sits approximately 2 kilobases upstream of the TCN2 gene — in the promoter-proximal region that governs how much transcobalamin II your liver and other tissues produce.

Unlike the well-studied TCN2 coding variant rs1801198 (Pro259Arg), which impairs the protein's ability to bind and release B12, rs5753231 affects a different level of regulation: the amount of TCN2 protein your body makes in the first place. The rare T allele is associated with higher circulating transcobalamin II levels — potentially translating to a modest advantage in B12 delivery capacity.

The Mechanism

rs5753231 falls in a 2KB upstream region²² 2KB upstream region
By convention, "2KB upstream" means within 2,000 base pairs of the gene's transcription start site — a region rich in regulatory elements including promoter sequences, enhancer-binding sites, and transcription factor recognition motifs of TCN2 on chromosome 22q12.2. Variants in this class of regulatory elements can alter gene expression by affecting transcription factor binding³³ transcription factor binding
Proteins that attach to specific DNA sequences upstream of a gene and control how frequently that gene is transcribed into mRNA, RNA stability, or promoter efficiency without changing the amino acid sequence of the resulting protein.

The T allele is associated with higher serum TCN2 protein — a pattern consistent with increased transcriptional activity at this locus. More TCN2 protein in circulation means a greater capacity to load and deliver cobalamin to peripheral tissues. The C allele (carried by most people) represents the population-average expression level.

Because this is a promoter-region variant rather than a missense change, its functional impact is probabilistic rather than structural: it shifts the average abundance of a fully functional protein rather than reducing that protein's per-molecule effectiveness.

The Evidence

Two independent large-scale protein GWAS have identified rs5753231-T as a cis-pQTL for serum TCN2 levels. The Sun et al. 2018 Genomic Atlas⁴⁴ Sun et al. 2018 Genomic Atlas
Sun BB et al. Genomic atlas of the human plasma proteome. Nature, 2018 — a landmark analysis of 1,478 plasma proteins in 3,301 healthy blood donors from the INTERVAL cohort — detected the rs5753231-T association with TCN2 protein at genome-wide significance (beta = 0.21, p = 8 × 10⁻¹³). This effect survived strict multiple-testing correction across the entire plasma proteome.

The Gudjonsson et al. 2022 serum protein GWAS⁵⁵ Gudjonsson et al. 2022 serum protein GWAS
Gudjonsson A et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nature Communications, 2022 independently replicated the association in 5,368 participants from the AGES-Reykjavik cohort (beta = 0.117, p = 3 × 10⁻⁷), confirming that the effect is not cohort-specific.

Both studies detect TCN2 protein quantity (total transcobalamin II in circulation) rather than functional holotranscobalamin (B12-loaded TCN2). Higher total TCN2 theoretically increases the pool available to be loaded with cobalamin, but the downstream functional significance — whether T allele carriers have meaningfully better cellular B12 delivery — has not been directly tested in dietary or clinical intervention studies. This places the clinical relevance at an emerging evidence level⁶⁶ emerging evidence level
Single studies or pQTL associations without clinical outcomes data; the biological direction is clear but the practical effect size for individuals has not been quantified.

ClinVar classifies rs5753231-T as benign/likely-benign for transcobalamin II deficiency, consistent with its protective (rather than loss-of-function) direction.

Practical Actions

For TT homozygotes, the pQTL data suggests a modestly elevated baseline transcobalamin II pool. The most practical implication is that standard B12 monitoring is appropriate, and holotranscobalamin (holoTC) testing — which directly measures the active B12 fraction — would give the most relevant picture of actual transport capacity.

For CC homozygotes (the majority), this is a neutral finding at this evidence level; no corrective action is indicated. The actionable variants for TCN2 are the coding changes in rs1801198 and rs1131603, which directly alter the protein's B12-binding function.

Interactions

rs5753231 is an independent secondary association signal at the TCN2 locus, distinct from the coding variant rs1801198 (Pro259Arg). The two variants capture different aspects of TCN2 biology: rs1801198 affects protein function (B12-binding efficiency), while rs5753231 affects protein abundance (expression level). Individuals carrying the GG genotype at rs1801198 (reduced binding efficiency) alongside the CC genotype at rs5753231 (lower expression) represent a double hit on transcobalamin function — although direct interaction studies are lacking.

The broader one-carbon metabolism pathway context is the same as for rs1801198: adequate cellular B12 is needed for methionine synthase (MTR, rs1805087) to recycle homocysteine, and methionine synthase reductase (MTRR, rs1801394) to keep that enzyme active. TCN2 variants upstream or coding both feed into the same pathway limitation when B12 delivery to cells is suboptimal.

Von Willebrand factor is the scaffold protein of primary hemostasis: it bridges platelets to exposed collagen at a vascular injury site, and it ferries coagulation factor VIII through the bloodstream. To function, VWF must assemble into massive chain-like multimers¹¹ multimers
Ultra-large VWF multimers can span hundreds of individual VWF subunits and are far more effective at capturing platelets under the high shear stress of arterial blood flow than small multimers. rs61754011 disrupts that assembly at its very first step.

The Mechanism

The VWF gene encodes a precursor protein (pro-VWF) that begins with a large propeptide — the D1 and D2 domains — that acts as a chaperone. Inside the Golgi apparatus²² Golgi apparatus
The cellular organelle where VWF propeptides dimerize and then oligomerize into multimers before being packaged for secretion, the D2 domain orchestrates disulfide-linked end-to-end joining of VWF dimers into the high molecular weight (HMW) multimer chains that give VWF its clotting efficacy. The Gly550Arg substitution — a glycine replaced by the bulkier, charged arginine — disrupts this multimerization step. The resulting VWF is secreted but lacks its largest, most hemostatically active multimers.

This mechanism defines VWD type 2A: qualitative VWF deficiency with selective loss of HMW multimers and a VWF activity-to-antigen ratio below 0.7. Factor VIII levels are typically normal to mildly reduced. On electrophoretic multimer analysis, the large multimer bands are absent or greatly diminished.

The rs61754011 variant shows autosomal recessive inheritance³³ autosomal recessive inheritance
Heterozygous family members of the index case were phenotypically normal or only mildly affected; the full VWD type 2A phenotype required homozygosity. This recessive pattern distinguishes it from most VWD type 2A mutations, which are dominant — the Gly550Arg D2 domain defect impairs multimerization when present in both alleles, but a single wild-type allele produces sufficient functional propeptide to support normal multimer assembly.

The Evidence

The Gly550Arg mutation was first identified by Schneppenheim et al. in 1995⁴⁴ first identified by Schneppenheim et al. in 1995
In a German kindred, the proband was homozygous Gly550Arg with epistaxis, easy bruising, and menorrhagia; heterozygous relatives were phenotypically normal or borderline-abnormal. Laboratory findings in the homozygote included absent HMW multimers on electrophoresis and a reduced VWF ristocetin cofactor (VWF:RCo) activity disproportionate to VWF antigen level (VWF:Ag) — the hallmark ratio of type 2 VWD. The variant was originally classified as VWD type IIC (propeptide-defective multimerization) and was re-classified as VWD type 2A under the current Sadler 2006 nosology⁵⁵ Sadler 2006 nosology
The updated classification unified VWD subtypes IIA, IIC, IID, IIE, and related propeptide-defect types under the single "type 2A" umbrella.

Because the variant is exceedingly rare in population databases (not detected in gnomAD or the ALFA population dataset across >10,000 chromosomes), population-level frequency estimates are unavailable. The recessive inheritance means most carriers (CT genotype) are unknown to themselves and require clinical investigation only if they have a consanguineous pedigree or a homozygous affected family member. ClinVar classifies the Gly550Arg allele as Pathogenic (VCV000000305) for VWD type 2A based on functional and clinical evidence.

Practical Actions

For homozygous carriers (TT), the clinical picture is von Willebrand disease type 2A — a moderate qualitative bleeding disorder. The cardinal symptoms are mucocutaneous bleeds: frequent or prolonged nosebleeds, easy bruising, gum bleeds, and in women, heavy menstrual periods. Joint bleeds are uncommon.

Management of VWD type 2A focuses on two therapeutic tools: Desmopressin (DDAVP) releases stored VWF from endothelial Weibel-Palade bodies, transiently raising VWF levels 3–5-fold. In type 2A it may provide partial benefit for minor bleeds, but the released VWF still lacks HMW multimers (because the defect is in propeptide-mediated assembly, not in release), so response is typically incomplete. A desmopressin trial under clinical supervision is necessary before relying on it for procedural prophylaxis. VWF concentrate (plasma-derived, e.g. Humate-P, Wilate) delivers functional VWF with a full multimer distribution and is the definitive treatment for major bleeds, surgery, and procedures when desmopressin response is insufficient.

Heterozygous carriers (CT) are typically clinically normal, though mildly reduced VWF:RCo values may appear on sensitive laboratory testing. No treatment is usually indicated, but formal assessment before elective surgery or invasive procedures is prudent.

Interactions

Because this variant follows autosomal recessive inheritance, the clinical risk in heterozygous carriers becomes significant primarily in the context of consanguinity (two carrier parents produce a 25% probability of a homozygous child). ABO blood group (rs505922 / ABO locus) is a major modifier of VWF levels in everyone: blood group O individuals have ~25% lower VWF than non-O, which can compound mild VWF quantitative reductions. However, for the Gly550Arg defect — which is a qualitative structural problem, not a quantitative one — ABO modulation is a secondary consideration. Clinicians managing affected individuals should assess the full coagulation profile including FVIII activity, VWF:Ag, VWF:RCo, and multimer electrophoresis to characterise individual phenotype severity.

The serotonin system runs on a delicate feedback loop. When serotonin neurons in the raphe nuclei¹¹ raphe nuclei
paired brainstem nuclei that are the brain's primary serotonin source, projecting widely to the cortex, limbic system, and hippocampus fire too strongly, they activate 5-HT1A autoreceptors on their own cell bodies. This autoreceptor acts as a brake, slowing firing and reducing serotonin output throughout the brain. The C-1019G variant in the HTR1A promoter determines how powerful that brake is — and for the roughly one in four people who carry two G alleles, the brake is permanently over-engaged.

The Mechanism

The C allele at position −1019 in the HTR1A promoter creates a binding site for a transcription factor called NUDR (also known as Deaf-1)²² NUDR (also known as Deaf-1)
Nuclear DEAF-1 Related transcriptional regulator; it represses HTR1A promoter activity specifically in serotonergic raphe neurons. When NUDR binds, it acts as a repressor — it keeps 5-HT1A autoreceptor expression at moderate, controlled levels in the raphe.

The G allele abolishes NUDR binding entirely. Without NUDR repression³³ Without NUDR repression
Czesak et al. showed Deaf-1 acts as a repressor in serotonergic cells but as an enhancer in non-serotonergic cells — the G allele disrupts this cell-type-specific braking only where it matters most, autoreceptor expression increases. More autoreceptors means more negative feedback on raphe firing. The serotonin system becomes chronically suppressed at its source — not because of a problem with serotonin itself, but because the gene controlling the brake is stuck in the "on" position.

Postmortem studies have found elevated 5-HT1A autoreceptor binding in raphe nuclei of depressed patients and suicide completers, consistent with this over-braking model. Albert's 2012 review⁴⁴ Albert's 2012 review
Paul R. Albert, Philosophical Transactions of the Royal Society B, 2012 synthesizes evidence that "opposing roles of pre- and post-synaptic 5-HT1A receptors" underlie both anxiety and depression phenotypes: overactive presynaptic autoreceptors reduce serotonin release, while glucocorticoid-driven suppression of postsynaptic heteroreceptors in hippocampus and prefrontal cortex completes the picture.

The Evidence

The landmark study came from Lemonde et al. in 2003⁵⁵ Lemonde et al. in 2003
Lemonde S et al., "Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide." Journal of Neuroscience, 2003. The GG genotype was enriched approximately twofold in patients with major depression versus controls (p=0.0017), and fourfold in completed suicide cases (p=0.002, allele p=0.00008). The same group followed this with a pharmacogenomics study: in 118 MDD patients⁶⁶ in 118 MDD patients
Lemonde S et al., International Journal of Neuropsychopharmacology, 2004, GG homozygotes were approximately twice as likely to be non-responders to antidepressants including fluoxetine and nefazodone (p=0.0497).

Population studies across East Asian and European cohorts have largely replicated the directional association. In 224 Taiwanese MDD patients, Hong et al. 2006⁷⁷ Hong et al. 2006
Hong CJ et al., Pharmacogenomics J, 2006 found that -1019C/C carriers had significantly better fluoxetine response (p=0.009). A companion study by Yu et al. 2006⁸⁸ Yu et al. 2006
Yu YW et al., European Neuropsychopharmacology, 2006 in 222 Chinese patients found the association was strongest in women. In a non-psychiatric context, Kraus et al. 2007⁹⁹ Kraus et al. 2007
Kraus MR et al., Gastroenterology, 2007 showed that HTR1A-1019G homozygosity predicted interferon-induced depression in 139 hepatitis C patients receiving interferon alfa-2b (p=0.017, OR=2.95).

However, meta-analyses have produced mixed results. A 2012 meta-analysis of 10 studies (Zhao et al., PMID 22890315) and a 2024 meta-analysis of 11 studies (Wu et al., PMID 39474388) both concluded "no significant association." The heterogeneity likely reflects differences in ethnicity (East Asian populations have G allele frequencies of ~0.76 versus ~0.49 in Europeans), antidepressant class, outcome definition, and study power. The evidence level for pharmacogenomic prediction is therefore rated strong rather than established — consistent directional effects but not yet clinical-grade.

Practical Actions

SSRIs work by blocking the serotonin transporter, keeping more serotonin in synapses. But if 5-HT1A autoreceptors in the raphe are overexpressed (as the G allele promotes), that extra synaptic serotonin triggers greater autoreceptor-mediated inhibition, dampening the drug's net effect. The brain compensates against the SSRI by turning down its serotonin output further.

This is why 5-HT1A autoreceptor strategies have been studied as augmentation approaches. Pindolol¹⁰¹⁰ Pindolol
a non-selective beta-blocker and 5-HT1A antagonist used off-label as an SSRI augmentation agent blocks the autoreceptor, preventing the feedback brake. Clinical trials have shown pindolol accelerates antidepressant response onset, though long-term benefit is debated. For GG carriers specifically, this pharmacological rationale is strongest.

Antidepressants with direct 5-HT1A activity — such as vilazodone (which is also a 5-HT1A partial agonist) and vortioxetine (which partially targets 5-HT1A) — desensitize the autoreceptor over time and may be better suited to carriers of the G allele than classical SSRIs. The 5-HT1A partial agonist buspirone has also been used as an augmentation strategy, with the rationale of desensitizing autoreceptors.

Note that all three meta-analyses agree that sex and ethnic background are important moderators. Women and East Asian individuals appear to show stronger genotype effects in most studies, so clinical interpretation should account for ancestry.

Interactions

The most important interaction is with the serotonin transporter gene SLC6A4, specifically the 5-HTTLPR insertion/deletion and its functional modifier rs25531. When a patient carries both the HTR1A GG genotype (overactive autoreceptor) and the SLC6A4 low-expression genotype (reduced serotonin transporter capacity), the compounding effect on serotonin dysregulation is significant. Lemonde et al. and subsequent investigators have noted that this combination is substantially overrepresented in treatment-resistant depression cohorts. The biological rationale is clear: reduced serotonin synthesis or release (autoreceptor effect) combined with reduced transporter capacity produces a profoundly dysregulated serotonin system that is difficult to target with standard SSRIs alone.

The HTR2A receptor gene (rs6311) interacts with HTR1A as a complementary post-synaptic target: where HTR1A controls presynaptic serotonin output, HTR2A mediates post-synaptic responsiveness. Patients with risk variants in both genes may require atypical antipsychotic augmentation (which targets HTR2A) alongside SSRI adjustment.

Paraoxonase-1 (PON1) is an enzyme that rides on HDL particles¹¹ HDL particles
High-density lipoprotein, often called "good cholesterol," transports cholesterol from tissues back to the liver in your bloodstream, where it performs two critical jobs: detoxifying organophosphate pesticides²² organophosphate pesticides
Compounds widely used in agriculture that can be neurotoxic; PON1 breaks down their active metabolites and protecting LDL cholesterol from oxidative damage³³ oxidative damage
Oxidized LDL is a key driver of atherosclerosis, the buildup of plaques in artery walls. The Q192R variant creates two functionally different versions of the enzyme with a striking tradeoff: the R variant is better at breaking down pesticides, while the Q variant is superior at preventing LDL oxidation and protecting against cardiovascular disease.

The Mechanism

The Q192R polymorphism results from an A>G nucleotide change that exchanges an arginine (R) for glutamine (Q) at position 192 of the protein . This amino acid substitution alters the enzyme's active site⁴⁴ active site
The region of an enzyme where substrates bind and chemical reactions occur, changing its catalytic efficiency for different substrates.

The Q isoform can reduce copper-mediated LDL oxidation by 58-61%, whereas the R genotype inhibits LDL oxidation by only 36-48% . However, the situation reverses for organophosphate metabolism— purified PON192 alloforms show the R variant has higher catalytic efficiency for hydrolysis of specific oxon substrates , making RR individuals better protected against pesticide poisoning but more vulnerable to cardiovascular disease.

The Evidence

The cardiovascular implications are substantial.

In a Saudi study of 2,456 individuals, the RR genotype was associated with CAD risk with an OR of 2.2 (95% CI 1.4-7.4, p < 0.01), independent of age, gender, smoking, obesity, and diabetes .

In Chinese Han individuals, after adjusting for conventional risk factors, 192R allele carriers had a significantly higher risk of CAD than other allele carriers . The mechanism is clear: the diminished ability of the RR variant genotype of PON1 to blunt LDL oxidation allows oxidized LDL to accumulate in artery walls.

Interestingly, the cardiovascular risk associated with the R allele shows ethnic variation⁵⁵ ethnic variation
Genetic risk can vary across populations due to differences in genetic background and environmental exposures.

In Asian populations, the 192R allele was a susceptible factor for type 2 diabetes, but represented a protective factor in the European population (OR = 0.66, 95% CI = 0.45-0.98) under a heterozygous genetic model . This may reflect different patterns of oxidative stress, diet, or gene-gene interactions across populations.

For organophosphate exposure, the evidence is also compelling.

A meta-analysis of nine studies with 1,042 patients showed that the PON1 192Q polymorphism increases the risk of organophosphate toxicity , with significant associations among Caucasian populations .

In Colombian coffee harvesters, the 192Q genotype was associated with hypertension , potentially reflecting both cardiovascular vulnerability and cumulative pesticide exposure effects.

Practical Implications

Your genotype shapes how your body handles two distinct challenges: protecting your arteries from oxidative damage and clearing environmental toxins. QQ individuals have superior antioxidant protection but are more vulnerable to organophosphate toxicity. RR individuals have the opposite profile—better pesticide clearance but reduced cardiovascular protection. Heterozygotes (QR) fall somewhere in between.

For cardiovascular health, tomato juice consumption reduced LDL oxidation and improved antioxidant status in R-allele carriers, but not in the QQ genotype group , suggesting dietary antioxidants may compensate for the R variant's reduced intrinsic antioxidant capacity. Polyphenol-rich foods (berries, green tea, dark chocolate, olive oil) provide similar oxidized LDL protection.

If you have occupational or recreational exposure to organophosphate pesticides (agricultural work, home gardening with conventional pesticides), your Q192R genotype affects your vulnerability. QQ individuals should be especially cautious about pesticide exposure, using protective equipment and favoring organic produce when practical.

Interactions

The Q192R polymorphism interacts with PON1 L55M (rs854560)⁶⁶ PON1 L55M (rs854560)
Another PON1 variant affecting enzyme expression levels; the M allele is associated with lower PON1 concentrations in the same gene.

The 55M homozygotes have over 50% less activity toward paraoxon compared to the LL and LM genotypes regardless of the 192 genotype, and the 55 polymorphism accounts for 16% of the variation in PON1 activity . The combination of Q192R with unfavorable L55M genotypes compounds cardiovascular risk and pesticide sensitivity.

In rheumatoid arthritis patients, the TLQ haplotype (combining promoter, L55M, and Q192R variants) was associated with low PON1 activity (OR = 2.29) and low PON1 protein levels (OR = 1.65) , demonstrating how multiple PON1 variants can synergistically impair enzyme function.

Inside every cell, a set of enzymes quietly edits transfer RNA — the molecular adaptors that read genetic code and build proteins. CDKAL1 encodes one of these editors: a methylthiotransferase¹¹ methylthiotransferase
An enzyme that adds a methylthio (-SCH₃) chemical group to a specific adenosine residue (ms²t⁶A₃₇) in tRNA, essential for accurate translation of codons beginning with adenosine that modifies tRNA at position 37, adjacent to the anticodon loop. This modification ensures the ribosome reads ANN codons faithfully — without it, mistranslation errors accumulate, affecting proteins whose synthesis depends on those codons. rs6908425 is an intronic variant in CDKAL1 whose C allele has been reproducibly associated with Crohn's disease risk across multiple large GWAS studies.

The Mechanism

rs6908425 sits in an intron of CDKAL1 at chromosome 6, position 20,728,500 (GRCh38). As an intronic variant it does not change the protein sequence directly, but it likely acts as a regulatory tag²² regulatory tag
Intronic variants can alter splicing efficiency, branch point usage, or intronic regulatory elements that control transcription. rs6908425 is in strong linkage disequilibrium with functional variants in CDKAL1 that affect gene expression levels.

Quaranta et al. (2009)³³ Quaranta et al. (2009)
Quaranta M et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes & Immunity, 2009 made a critical observation: CDKAL1 transcripts are virtually absent from skin keratinocytes but are abundantly expressed in immune cells — particularly CD4+ T lymphocytes and CD19+ B lymphocytes — and are markedly downregulated when those cells receive proliferating signals. This expression pattern explains why CDKAL1 variants influence immune-mediated diseases: the gene's tRNA modification activity is most important in actively translating immune cells. Impaired tRNA editing in lymphocytes may reduce the fidelity of cytokine and receptor protein synthesis, contributing to dysregulated immune activation.

The Evidence

Barrett et al. (2008)⁴⁴ Barrett et al. (2008)
Barrett JC et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics, 2008 identified rs6908425-C as a Crohn's disease susceptibility allele with OR 1.21 (P=9×10⁻¹⁰) in a large multi-stage GWAS. This was replicated by Liu et al. (2015)⁵⁵ Liu et al. (2015) in a larger IBD meta-analysis (OR 1.11, P=5×10⁻¹²), and by Franke et al. (2010)⁶⁶ Franke et al. (2010) (OR 1.17, P=1×10⁻⁸). The same GWAS data showed a weaker ulcerative colitis association (OR 1.07, P=4×10⁻⁶), indicating the primary signal is in Crohn's disease specifically.

Quaranta et al. (2009)⁷⁷ Quaranta et al. (2009)
Quaranta M et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes & Immunity, 2009 demonstrated that CDKAL1's risk allele for Crohn's disease and psoriasis is independent of the CDKAL1 T2D association: the same genomic region harbors distinct alleles driving disease-specific risk through different cell types. For psoriasis, the rs6908425 association reached OR 1.26–1.28 (combined P=4×10⁻⁶ across 2,579 cases and 4,306 controls).

Umeno et al. (2011)⁸⁸ Umeno et al. (2011)
Umeno J et al. Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. Inflammatory Bowel Disease, 2011 confirmed CDKAL1 among eight loci with modest effect sizes (OR 1.05–1.22) shared across IBD phenotypes. Evidence is strong: consistent replication across independent European and international cohorts with cumulative sample sizes in the tens of thousands.

The variant also shows a modest negative association with body mass index (beta −0.0095 per C allele, P=2×10⁻⁹) in a 2022 GWAS, consistent with CDKAL1's broader metabolic role in pancreatic beta cells and tRNA-mediated translational fidelity.

Practical Actions

Carrying one or two copies of the C allele does not guarantee Crohn's disease — it modestly shifts population-level risk. The C allele is common (~79% globally), meaning most people carry it. The actionable value for CC homozygotes lies in earlier vigilance for gastrointestinal symptoms, understanding of specific dietary patterns that support the intestinal mucosal barrier in genetically susceptible individuals, and awareness that anti-TNF biologic therapy is particularly relevant to this genetic risk pathway.

Crohn's disease in CDKAL1 C-allele carriers arises from a dysregulated mucosal immune response — supporting gut barrier integrity through targeted dietary and supplement strategies is genotype-relevant advice for CC individuals with gastrointestinal symptoms.

Interactions

CDKAL1 rs6908425 is part of a broader inflammatory genome. Its Crohn's disease signal is independent from the CDKAL1 T2D risk variants, demonstrating allelic heterogeneity at this locus. Individuals carrying both CDKAL1 risk alleles and IL23R risk alleles (rs11209026, rs2201841) have compounding risk for inflammatory bowel disease through the IL-23/Th17 pathway that governs mucosal immune responses in the gut. IBD risk is highly polygenic, and CDKAL1 C-allele status should be interpreted alongside ATG16L1, NOD2, and IL23R genotypes when available.

Ghrelin is the body's primary hunger hormone — produced mainly in the stomach, it rises sharply before meals and falls after eating to signal fullness. This rise-and-fall cycle is essential for normal appetite regulation. The rs696217 variant (Leu72Met) substitutes leucine for methionine at position 72 of the preproghrelin protein — a region located between the mature ghrelin peptide and the obestatin segment¹¹ between the mature ghrelin peptide and the obestatin segment
The GHRL gene encodes a 117-amino-acid precursor; mature ghrelin is only 28 amino acids; position 72 sits in the C-terminal tail, outside mature ghrelin but within a region that influences processing and secretion. While the variant doesn't alter the mature ghrelin sequence itself, it appears to disrupt prohormone processing and mRNA stability²² disrupt prohormone processing and mRNA stability
The substitution may change how efficiently preproghrelin is cleaved, altering total ghrelin output and postprandial suppression kinetics, producing measurable downstream effects on appetite, lipid profiles, and metabolic disease risk.

The Mechanism

After a meal, postprandial ghrelin suppression³³ postprandial ghrelin suppression
Normally, eating causes ghrelin levels to drop by 30–50% within 60 minutes, signaling fullness to the hypothalamus is the key satiety signal from the gut. In carriers of the Met72 (T) allele, this suppression is blunted: ghrelin levels at 120 minutes postprandially remain significantly elevated compared to Leu72 homozygotes. The hypothalamus interprets persistently elevated ghrelin as continued hunger, driving greater food intake — particularly of high-sugar and high-starch foods. The variant may also affect obestatin co-processing⁴⁴ obestatin co-processing
Obestatin, a satiety peptide encoded in the same preproghrelin region, may be altered when the flanking amino acid at position 72 changes, further shifting the appetite balance toward hunger. Downstream effects include lower HDL-C, altered insulin sensitivity, and elevated adipokine profiles (decreased adiponectin, increased resistin) — together constituting the metabolic syndrome phenotype.

The Evidence

The landmark population study came from the Old Order Amish, where Korbonits et al. examined 856 adults⁵⁵ Korbonits et al. examined 856 adults
Amish Family Diabetes Study; comprehensive phenotyping including fasting glucose, lipids, insulin, waist circumference and found that Leu72Met carriers had a 2.57-fold higher odds of metabolic syndrome, with concurrently higher fasting glucose, lower HDL-C, and elevated triglycerides.

A 2018 meta-analysis of 13 case-control studies⁶⁶ 2018 meta-analysis of 13 case-control studies
Total 8,926 participants; 4,720 T2DM cases and 4,206 controls; studies from Europe, Asia, and the Arab world revealed a striking ethnic split: the T allele increases type 2 diabetes risk in Asians (OR 1.34, p = 0.040) but appears protective in Caucasians (OR 0.79, p = 0.030). The mechanism of this discordance is not fully understood but may reflect differences in linkage disequilibrium, epistatic background, or dietary environments across populations.

In a Turkish-Cypriot cohort of 211 adults⁷⁷ Turkish-Cypriot cohort of 211 adults
106 obese vs. 95 non-obese, rigorously phenotyped, the T allele appeared at 38% frequency in obese subjects vs. 22% in controls, with GT heterozygotes showing significantly lower HDL-C. A 2021 case-control study (310 participants)⁸⁸ 2021 case-control study (310 participants)
Biopsy-proven NAFLD diagnosis in 153 cases vs. 157 controls found the opposite pattern for fatty liver: GT/TT genotypes were substantially less common among NAFLD patients (OR 0.35), suggesting the Met72 allele may protect against fat accumulation in the liver while increasing it elsewhere.

The most clinically striking finding comes from a bariatric surgery cohort⁹⁹ bariatric surgery cohort
100 severely obese patients undergoing Roux-en-Y gastric bypass: GT heterozygotes lost 38.1% of BMI at 52 weeks vs. 30.5% in GG homozygotes (p < 0.001), suggesting the Met72 allele actually facilitates greater ghrelin reduction post-surgery and better weight loss outcomes.

A dietary intake study in 132 young adults¹⁰¹⁰ in 132 young adults
77% female, age 22 years, standardized meal challenge confirmed that Met allele carriers consumed significantly more fruit servings and added-sugar-containing bread and starch, consistent with impaired postprandial satiety driving sugar-seeking behavior.

Practical Implications

For GG homozygotes (the large majority), ghrelin dynamics are standard. For T allele carriers, the impaired postprandial suppression creates a biological drive toward higher food intake — particularly sugary and starchy foods — that is real, not a matter of willpower. High-protein meals suppress ghrelin more effectively than carbohydrate-rich meals and can compensate for the blunted suppression signal. Spacing meals with adequate protein and fiber, and avoiding rapid glycemic spikes that cause early return of hunger, are particularly important strategies for this genotype. Monitoring fasting glucose, HDL-C, and triglycerides annually is warranted given the metabolic syndrome associations, especially in populations where the T allele confers risk rather than protection.

Interactions

rs696217 interacts with the ghrelin promoter variant rs27647¹¹¹¹ rs27647
A-604G promoter SNP; affects GHRL transcription levels; may modulate total ghrelin output independently of processing changes at position 72. Carriers of T allele at rs696217 who also carry the risk allele at rs27647 may face compounded disruption of ghrelin regulation — affecting both total ghrelin levels (rs27647) and postprandial suppression (rs696217). The leptin system also interacts: ghrelin and leptin act in opposition on hypothalamic appetite circuits, and LEPR variants such as Gln223Arg¹²¹² LEPR variants such as Gln223Arg
Leptin receptor polymorphism that reduces leptin signaling efficacy can compound the appetite dysregulation from impaired ghrelin suppression. When both ghrelin fails to suppress after meals and leptin fails to signal fullness adequately, the combined effect on caloric intake and weight gain may be substantially larger than either variant alone.

Uterine fibroids (leiomyomas) are benign smooth muscle tumors of the uterus that affect up to 70–80% of women by age 50, causing heavy menstrual bleeding, pelvic pain, and in some cases impaired fertility. Their growth is driven by complex interactions between hormones, genomic instability, and abnormal cell proliferation. rs7907606 is an intergenic variant sitting between two genes with compelling biological relevance to fibroid formation: STN1 (also called OBFC1)¹¹ STN1 (also called OBFC1)
STN1 is a subunit of the CST complex (CTC1-STN1-TEN1) that protects telomere ends and coordinates telomere replication with DNA polymerase alpha-primase and SLK²² SLK
SLK is a serine/threonine kinase involved in cytoskeletal organization, focal adhesion assembly, actin polymerization, and cell migration. Multiple independent GWAS have pinpointed this locus as a reproducible fibroid susceptibility region.

The variant is intergenic — it does not alter a protein directly — and its functional effect appears to be regulatory: it likely modulates the expression of STN1, SLK, or both in uterine tissue. A 2019 trans-ethnic GWAS found that genetically-predicted expression of OBFC1 in esophageal mucosa (a proxy tissue) was significantly associated with fibroid risk³³ A 2019 trans-ethnic GWAS found that genetically-predicted expression of OBFC1 in esophageal mucosa (a proxy tissue) was significantly associated with fibroid risk
P=8.7×10⁻⁸, from Edwards et al. 2019, supporting a gene-expression mechanism rather than a protein-coding one.

Two biological pathways connect these genes to fibroid development. First, the STN1/CST complex maintains telomere integrity — and telomere length itself has a documented causal role in fibroid risk⁴⁴ documented causal role in fibroid risk
Mendelian randomization: genetically longer telomeres increase leiomyoma risk OR=1.73, p=4.9×10⁻¹⁶. Longer telomeres enable smooth muscle cells to undergo more rounds of replication before senescence, which may allow pre-malignant or hormonally dysregulated cells to accumulate the additional mutations required for fibroid initiation. Second, SLK controls cytoskeletal dynamics and focal adhesion assembly — processes that govern how smooth muscle cells attach to the extracellular matrix and migrate within the myometrium. Altered SLK activity could promote the aberrant proliferation and tissue remodeling that characterizes fibroid growth.

The fibroid association at this locus has been replicated across multiple large independent studies. Rafnar et al. (2018) performed a meta-analysis in 16,595 European cases and 523,330 controls⁵⁵ Rafnar et al. (2018) performed a meta-analysis in 16,595 European cases and 523,330 controls
Nature Communications and identified rs7907606 at the OBFC1/STN1 locus as one of 21 variants at 16 genome-wide significant loci, with OR 1.10 (p=3×10⁻⁹). The paper noted that several fibroid loci — including this one — overlapped with loci for other tumors, suggesting shared cancer-related biology. Edwards et al. (2019) extended this work in a trans-ethnic cohort of 21,804 cases⁶⁶ Edwards et al. (2019) extended this work in a trans-ethnic cohort of 21,804 cases
combining eMERGE network data with UK Biobank and confirmed the OBFC1 locus with even stronger evidence (p=2×10⁻¹⁶, OR 1.12, 95% CI 1.09–1.15).

At the clinical level, Ponomareva et al. (2024) genotyped 737 fibroid patients and 451 controls in Russia⁷⁷ Ponomareva et al. (2024) genotyped 737 fibroid patients and 451 controls in Russia
Front Biosci Schol Ed and found an OR of 1.34 (95% CI 1.03–1.74, p=0.028) in women without prior pelvic inflammatory disease — suggesting that infection-related inflammation may mask the genotype effect in women with PID history. Notably, this study identified a significant gene-gene interaction between rs7907606 and rs547025 in SIRT3 (a mitochondrial deacetylase involved in oxidative stress response), which together contributed the most information to fibroid risk entropy of any variant pair tested. This interaction hints at a combined telomere/oxidative stress axis in fibroid susceptibility.

Population frequencies are notably higher in women of African ancestry (G allele ~49%) than in European (16%) or East Asian (18%) populations. This disparity is clinically relevant: African American women have 2–3 times higher fibroid incidence and more severe disease than European American women, and genetic factors at loci like this one may contribute to that disparity.

This is a GWAS susceptibility locus with a moderate effect size (OR 1.10–1.34 per copy), not a deterministic mutation. Having one or two copies of the G allele increases risk but does not cause fibroids. The clinical relevance lies in knowing your risk profile to guide appropriate surveillance — specifically, earlier or more frequent pelvic ultrasound screening for women who are symptomatic or have a family history of fibroids.

Symptom awareness matters: heavy menstrual bleeding, pelvic pressure or pain, frequent urination, or pain during intercourse are common fibroid symptoms that warrant evaluation. Many fibroids are asymptomatic and require no intervention; symptomatic cases have multiple treatment options ranging from medication to minimally invasive procedures.

The interaction with SIRT3 (mitochondrial antioxidant regulation) suggests that oxidative stress management — particularly relevant if you also carry risk variants in oxidative stress pathways — may be biologically meaningful context, though direct intervention evidence for this locus is not yet established.

rs547025 (SIRT3): The strongest gene-gene interaction in fibroid risk identified by Ponomareva et al. (2024) was between rs7907606 and rs547025 in SIRT3, a mitochondrial deacetylase that regulates oxidative phosphorylation and reactive oxygen species production. The combined effect was the largest single pairwise contributor to fibroid risk entropy in that study. The biological model: telomere maintenance stress (STN1/SLK locus) combined with impaired mitochondrial antioxidant activity (SIRT3) may create a permissive cellular environment for fibroid initiation.

rs12696304 (TERC): The TERC locus (telomerase RNA component) directly regulates telomere length. Women who carry risk alleles at both the STN1 locus (rs7907606) and the TERC locus (rs12696304-G) may have additive effects on telomere biology, potentially amplifying the shared causal pathway (longer functional telomere length → greater fibroid susceptibility) identified in the Mendelian randomization data.

The chromosome 2q12 region is one of the most densely connected immune susceptibility loci in the human genome. Packed into a span of less than 300 kilobases are several interleukin-1 receptor family members — IL1RL1 (encoding the IL-33 receptor ST2), IL18R1, and IL18RAP — all of which form a tightly co-regulated signaling hub that links innate immune sensing to Th1 and type-2 inflammatory cascades. rs9807989 sits approximately 1 kilobase upstream of the IL18R1 transcription start site, in a position to influence how much IL-18 receptor is available on immune cell surfaces.

The Mechanism

IL-18¹¹ IL-18
Interleukin-18; an inflammasome-activated cytokine that drives IFN-γ production from T helper 1 cells, NK cells, and NKT cells — a key bridge between innate detection and adaptive Th1 amplification binds a two-chain receptor complex composed of IL-18R1 (the ligand-binding α chain) and IL18RAP (the signal-transducing β chain). When IL-18 binds this complex, it activates NF-κB and MAPK pathways, driving IFN-γ secretion and amplifying macrophage and NK cell activity. The upstream position of rs9807989 places it in the gene's regulatory region, where T/C variation in transcription factor binding sites can affect IL18R1 transcript levels — altering how efficiently immune cells respond when IL-18 is released from activated inflammasomes.

The locus is in partial linkage disequilibrium with the adjacent rs2287037 promoter SNP and the IL18RAP variant rs917997, both of which have been shown to have large cis-effects on receptor expression. Trynka et al. (J Immunology, 2014)²² Trynka et al. (J Immunology, 2014)
IL18RAP region disease polymorphism decreases IL-18RAP/IL-18R1/IL-1R1 surface expression and downstream signaling capacity demonstrated that risk alleles in this region reduce receptor surface availability on monocyte-derived macrophages, impairing MAPK, NF-κB, and calcium-flux responses to both IL-18 and NOD2 stimulation. The haplotype structure of this locus means rs9807989 acts as a tag for cumulative regulatory variation across IL18R1 and its flanking partners.

The Evidence

The most direct evidence for rs9807989 comes from a 2025 case-control study of chronic obstructive pulmonary disease. Ren et al. (Annals of Medicine, 2025)³³ Ren et al. (Annals of Medicine, 2025)
Identification of genetic variants of the IL18R1 gene in association with COPD susceptibility genotyped rs9807989 in 996 subjects (498 COPD cases, 498 healthy controls). The C allele showed strongly protective association against COPD in all tested models — allele (OR 0.42, p<0.001), dominant (OR 0.39, p<0.001), and recessive (OR 0.20, p=0.014). Haplotype analysis placed rs9807989 in Block 1 with the promoter SNP rs2287037; the T(rs9807989)/T(rs2287037) haplotype was associated with increased COPD risk (OR 2.32, p<0.001), confirming additive effects within the LD block.

The broader 2q12 locus is one of the most replicated signals in inflammatory disease genetics. Parkes et al. (Am J Hum Genet, 2008)⁴⁴ Parkes et al. (Am J Hum Genet, 2008)
Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies susceptibility loci harboring IL18RAP demonstrated that variants in the IL1RL1-IL18R1-IL18RAP cluster reach genome-wide significance for both Crohn's disease and ulcerative colitis combined (OR 1.35, p=1.9×10⁻⁸) in 1,851 IBD patients and 1,936 controls. Festen et al. (PLoS Genetics, 2011)⁵⁵ Festen et al. (PLoS Genetics, 2011)
Meta-analysis of GWAS identifies IL18RAP as shared risk locus for Crohn's disease and celiac disease extended these findings, showing shared 2q12 genetic risk across two distinct autoimmune diseases, with the IL18RAP signal reaching p=8.37×10⁻⁸ in combined analysis.

Functionally, the risk alleles at this locus — including the T allele at rs9807989 — are associated with dysregulated IFN-γ responses. Myhr et al. (J Autoimmunity, 2013)⁶⁶ Myhr et al. (J Autoimmunity, 2013)
The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFN-γ production by PBMC showed that cells carrying the susceptibility genotype produce significantly more IFN-γ after IL-12 and IL-18 stimulation (P=0.0296), along with reduced IL-18RAP and IL-18R1 surface protein expression on NK cells — a pattern consistent with compensatory upregulation of remaining receptor complexes or autocrine amplification loops.

Practical Actions

The T risk allele at rs9807989 operates through heightened inflammatory signaling at the IL-18 receptor axis. Relevant actions focus on monitoring biomarkers of IL-18-driven inflammation and managing modifiable factors that activate inflammasomes — the cellular machinery that cleaves IL-18 into its active form.

Interactions

rs9807989 is in linkage disequilibrium with the IL18R1 promoter SNP rs2287037 (same Block 1 haplotype). The adjacent locus tags rs3771166 (IL18R1 intron, GABRIEL asthma GWAS lead) and rs1420101 (IL1RL1 intron, IL-33 pathway sST2 eQTL) represent partially independent signals within the same chromosomal region. Individuals carrying risk alleles at multiple 2q12 nodes accumulate additive susceptibility across the IL-33 and IL-18 receptor arms simultaneously. The IL18RAP variant rs917997 (in LD with the region) is the most studied functional variant at this locus and the primary GWAS signal for IBD and celiac disease association.

Every naïve T cell faces a binary decision when it encounters an antigen: become a Th1 fighter that floods tissue with interferon-gamma (IFN-gamma) to combat intracellular pathogens, or become a Th2 helper that drives IgE and eosinophil-based responses against parasites and allergens. The master switch for the Th1 path is T-bet¹¹ T-bet
encoded by TBX21 (T-box transcription factor 21); the transcription factor that directly activates the IFNG promoter, represses GATA3 and Th2 differentiation, and commits CD4+ T cells to the Th1 effector lineage. rs17699436 sits approximately 5 kb downstream of the TBX21 gene in the intergenic region between TBX21 and OSBPL7 on chromosome 17q21.32. It has been cited alongside TBX21-region variants in association studies of systemic autoimmune disease and is presumed to tag regulatory variation influencing the TBX21-IFNG transcriptional axis.

The Mechanism

rs17699436 maps to chr17:47,751,209 (GRCh38), positioned roughly 5 kilobases 3-prime of the TBX21 transcription end site (chr17:47,746,122). The A>G substitution lies in a region that Ensembl classifies as an intergenic variant with low evolutionary conservation (GERP score −0.48). Its functional significance is not established by direct in vitro assay, but its co-citation with TBX21 promoter and intronic variants in haplotype studies suggests it may be in linkage disequilibrium with regulatory elements that control TBX21 expression. The downstream consequence, if the G allele does tag reduced TBX21 activity, would be blunted T-bet protein output in activated CD4+ T cells — the same mechanism documented for the better-characterized rs4794067 promoter variant.

Fyall et al. (2012)²² Fyall et al. (2012) directly quantified TBX21 promoter variant effects on cytokine output in 210 healthy donors: CC carriers at rs4794067 produced significantly less IFN-gamma (p=0.02) and IL-4 (p=0.001) than TT individuals. If rs17699436 tags this same haplotype block, G-allele carriers would be expected to show a similar, if attenuated, reduction in T-bet-driven IFN-gamma production.

The Evidence

The two publications that index rs17699436 are both systemic autoimmune disease studies. Gourh et al. (2009)³³ Gourh et al. (2009) studied TBX21-region variants in 902 SSc patients and 4,745 controls, finding TBX21 polymorphisms associated with altered Th1/Th2 cytokine balance: SSc patients carrying the high-risk TBX21 haplotype had elevated Th2 cytokines (IL-4, IL-5, IL-13) consistent with reduced T-bet suppression of the Th2 program. rs17699436 was cited as a TBX21-region marker in this context. Leng et al. (2016)⁴⁴ Leng et al. (2016) studied the TBX21/IFNG interaction axis specifically — analyzing rs4794067 (TBX21) against rs2069705 (IFNG) in a 3,732-subject Chinese SLE cohort and found a significant gene-gene interaction: neither variant alone reached significance for SLE susceptibility, but their combination did. This finding establishes the TBX21-IFNG regulatory axis as a unit with compounded autoimmune risk potential.

The broader context for this locus in immune disease comes from studies of the TBX21 haplotype. Munthe-Kaas et al. (2008)⁵⁵ Munthe-Kaas et al. (2008) identified TBX21 intronic variants associated with allergic asthma in Norwegian children with an odds ratio of 8.3 (95% CI 2.5–26.9) for homozygous risk-haplotype carriers, specifically for allergic (IgE-mediated) asthma but not non-allergic asthma. This specificity supports the mechanism: reduced T-bet activity fails to suppress Th2 responses to common allergens, leading to IgE sensitization and airway inflammation.

It is important to be transparent: the direct functional effect of rs17699436 itself has not been independently characterised. The evidence for the G allele's clinical significance is moderate — drawn from haplotype context and co-segregation with better-characterized TBX21 variants — rather than from direct functional assays or independent association studies focused exclusively on rs17699436.

Practical Implications

For G allele carriers, the primary consideration is awareness of the TBX21 regulatory axis: if this variant tags reduced T-bet activity, the practical implications mirror those of other TBX21 hypomorphic variants — a modest shift toward Th2-dominant immune responses with corresponding susceptibility to IgE-mediated allergy, reduced IFN-gamma-driven pathogen defense, and potential vulnerability to autoimmune conditions where the Th1/Th2 balance is mechanistically important. The rarity of GG homozygosity (~0.6% globally) means most carriers are AG heterozygotes, for whom the directional effect is present but attenuated relative to the better-studied CC and TT homozygote patterns at rs4794067.

Interactions

The most established interaction within this locus is between TBX21 and IFNG: T-bet directly binds the IFNG promoter and transactivates IFN-gamma gene expression. Leng et al. (2016) demonstrated that TBX21 and IFNG promoter variants interact epistatically in determining SLE susceptibility — disrupting both ends of the T-bet→IFN-gamma signal chain compounds autoimmune risk beyond either variant alone. Carriers of rs17699436 G who also carry the rs2069705 risk allele in the IFNG promoter may face additive disruption of this axis. The TBX21 haplotype containing rs11650354 and rs16947078 defines the allergic asthma risk in European children; if rs17699436 is in LD with this haplotype block, its allergy-relevant risk operates through the same Th2-permissive mechanism. The rs4794067 promoter variant is the most functionally characterized entry point into this regulatory network and should be checked alongside rs17699436 when assessing T-bet axis risk.

The TNFRSF1A gene encodes TNF receptor 1 (TNFR1)¹¹ TNF receptor 1 (TNFR1)
the primary signaling receptor for tumor necrosis factor-alpha, expressed on nearly all nucleated cells, a central mediator of inflammation and immune defense. When TNF-alpha binds TNFR1, it can trigger apoptosis, pro-inflammatory gene activation, or cell survival depending on context. In the central nervous system, TNF signaling plays a particularly complex role: certain TNF signals are neuroprotective and promote myelin repair, while others drive inflammation. This duality explains one of the most important drug paradoxes in modern medicine: anti-TNF biologics like infliximab, adalimumab, and etanercept — transformative drugs for rheumatoid arthritis and Crohn's disease — consistently worsen multiple sclerosis. A splice-region variant in TNFRSF1A, rs1800693, now explains precisely why.

The Mechanism

rs1800693 sits at the 3′ end of exon 6, 10 nucleotides into the flanking intron, at a position that influences how the pre-mRNA is spliced. The risk allele (C on the plus strand) promotes skipping of exon 6²² The risk allele (C on the plus strand) promotes skipping of exon 6
Exon 6 encodes the transmembrane and cytoplasmic anchor domains of TNFR1; skipping it creates a truncated, secreted protein during mRNA processing. The resulting truncated protein — called TNFRSF1A Δ6, or Δ6-TNFR1 — retains the extracellular TNF-binding domain but lacks the transmembrane and intracellular signaling portions. Without an anchor to the cell membrane, Δ6-TNFR1 is secreted as a soluble, circulating decoy receptor³³ soluble, circulating decoy receptor
Δ6-TNFR1 binds TNF-alpha in the bloodstream and blocks it from engaging membrane-bound TNFR1, with weaker affinity than full-length TNFR1 but still functionally relevant that soaks up free TNF-alpha before it can activate inflammatory signaling.

The Δ6 isoform represents on average 27% of total TNFRSF1A transcript in CC homozygotes, making it a substantial contributor to TNFR1 biology. The key insight from Gregory et al. (Nature, 2012)⁴⁴ Gregory et al. (Nature, 2012)
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis is that Δ6-TNFR1 does exactly what anti-TNF drugs do — it neutralizes TNF-alpha — but at a lower magnitude and with tissue-specific effects the pharmaceutical agents cannot replicate.

The Evidence

De Jager and colleagues⁵⁵ De Jager and colleagues
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nature Genetics 2009 first identified the TNFRSF1A locus in a GWAS meta-analysis of 2,624 MS cases and 7,220 controls, achieving combined p = 1.59×10⁻¹¹. The rs1800693 C allele showed an odds ratio of 1.2 — modest but highly significant due to its common frequency (~41% in Europeans). The locus contains two independent MS-associated variants: rs1800693 (common, OR 1.2) and the nearby coding variant rs4149584/R92Q (rare, 2% allele frequency, OR 1.6).

Replication across 11 European populations⁶⁶ Replication across 11 European populations
Genetic association of variants in CD6, TNFRSF1A and IRF8 to MS: a multicenter case-control study. PLoS ONE 2011 in 7,665 MS cases and 8,051 controls confirmed the association of rs1800693 (p = 4.19×10⁻⁷, OR = 1.12), cementing the locus as a true MS susceptibility signal.

The mechanistic breakthrough came with Gregory et al. Nature 2012⁷⁷ Gregory et al. Nature 2012
rs1800693 C allele generates Δ6-TNFR1, a soluble TNF antagonist explaining why anti-TNF drugs worsen MS: the C allele generates Δ6-TNFR1, which has nanomolar TNF-binding affinity and can neutralize TNF signaling in the CNS — the same mechanism exploited by pharmaceutical TNF inhibitors. Since pharmacological TNF blockade consistently worsens MS (multiple clinical trials were terminated early for this reason), and the rs1800693 C allele generates an endogenous TNF antagonist, this provides a compelling genetic explanation for why anti-TNF therapy is harmful in MS.

Clinical follow-up in 772 MS patients⁸⁸ Clinical follow-up in 772 MS patients
Clinical relevance and functional consequences of the TNFRSF1A MS locus. Neurology 2013 found that rs1800693(C) primarily affects disease onset rather than progression, and that C allele carriers show enhanced monocyte transcriptional responses to TNF-alpha including CXCL10 upregulation. A clinical study of 2,032 MS patients⁹⁹ clinical study of 2,032 MS patients
TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with MS. Neurology 2013 confirmed no severity effect of rs1800693 on disease course.

Practical Implications

The pharmacogenomic significance of this variant is profound. All five approved anti-TNF biologic agents — infliximab (Remicade), adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi), and certolizumab (Cimzia) — carry warnings about new-onset or worsening demyelinating disease, and are absolutely contraindicated in patients with MS or demyelinating disorders. The rs1800693 locus provides the mechanistic explanation: blocking TNF-alpha in the CNS disrupts neuroprotective TNF signaling through TNFR2 and impairs myelin repair mechanisms that are distinct from the peripheral inflammatory effects where anti-TNF therapy is beneficial.

For patients with an autoimmune condition requiring biologic therapy, awareness of this variant helps contextualize the risk. If you develop an inflammatory condition like rheumatoid arthritis or Crohn's disease AND experience neurological symptoms suggestive of demyelination, anti-TNF therapy becomes contraindicated regardless of genotype. The genotype contextualizes the underlying susceptibility mechanism, not just drug risk in isolation.

Interactions

The TNFRSF1A locus harbors two independent MS susceptibility variants: rs1800693 (this entry, common, splice-region) and rs4149584 (R92Q, rare coding variant, OR = 1.6). These are not in strong linkage disequilibrium (r² = 0.041 in HapMap CEU) and confer independent risk. rs4149584/R92Q also causes TRAPS (TNF receptor-associated periodic syndrome)¹⁰¹⁰ TRAPS (TNF receptor-associated periodic syndrome)
an autoinflammatory disorder with recurrent fever, myalgia, abdominal pain, and conjunctivitis at low penetrance — a distinct phenotype from the MS susceptibility conferred by rs1800693.

In the broader TNF pathway, the related promoter variant rs1800629 (TNF-308 G>A in the TNF gene itself) drives elevated TNF-alpha production. These variants interact at a pathway level: high TNF production (rs1800629 A allele) combined with impaired TNF-TNFR1 signaling via the Δ6 decoy isoform (rs1800693 C allele) could perturb the fine-tuned balance of TNF signaling critical in the CNS. No formal compound analysis of these two variants in MS has been published, but the mechanistic logic supports compound monitoring if both risk alleles are present.